MEDIUMBuilt-in & outside partyProduct / Revenue mix
ETUARY® (pirfenidone)
“10-K Item 1A: 'Our business is significantly dependent on the sales of ETUARY®, one of our marketed products in the PRC'”
GYRE · Concentration risk · 10-K extracted
Gyre Therapeutics (GYRE) concentration risks
Updated
The most significant concentration Gyre Therapeutics discloses is ETUARY® (pirfenidone), classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Gyre Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH0
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Gyre Therapeutics' concentration risk is centered on a single marketed product: the company discloses that its business is significantly dependent on sales of ETUARY® (pirfenidone), one of its marketed products in the People's Republic of China. This is a mixed-character exposure — it reflects both the structural reality of a specialty pharmaceutical company built around a small number of approved products, and the more idiosyncratic risk that pricing, reimbursement, or competitive dynamics affecting this one product in the PRC market could disproportionately affect overall results. No specific percentage of revenue is disclosed among the sourced claims, so the size of this dependency cannot be quantified beyond the company's own characterization of it as significant. For an educated investor, the practical takeaway is that Gyre's near-term results are closely tied to the commercial trajectory of a single product in a single country market, which narrows the range of outcomes relative to a more diversified pharmaceutical portfolio, even though the filing does not provide a percentage figure to size the exposure precisely.
For the engine’s reasoning on GYRE’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| GYRE● | Gyre Therapeutics, Inc. | 0 | 1 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.